NU Skin Enterprises Inc

NU Skin Enterprises Inc(NUS)の株式分析

$4.990

+0.308 (+6.17%)終値時点

Loading chart…
高値
5.130
始値
4.830
出来高加重平均価格
4.98
出来高
646.13K
時価総額
536.41M
安値
4.830
売買代金
3.22M
EV/EBITDA(TTM)
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

www.nuskin.com

AI分析 of NU Skin Enterprises Inc (NUS)

買い

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

アナリスト評価(6)

買い
3 買い
1 中立
2 売り
現在: 4.99
安値
—
平均
—
高値
—

DA Davidson

2024-12-20

目標株価

$7

中立

Citigroup

2024-10-22

目標株価

$6.75

中立

DA Davidson

2024-08-12

目標株価

$11

中立

Citigroup

2024-08-09

目標株価

$12

中立

DA Davidson

2024-05-09

目標株価

$13

中立

バリュエーション指標

NU Skin Enterprises Inc(NUS)の現在の予想PERは4.12で、5年平均は11.03です。

予想PER

割安
5年平均 P/E
11.03
現在のP/E
4.12
割高
16.12
割安
5.93

予想EV/EBITDA

割安
5年平均 EV/EBITDA
5.36
現在のEV/EBITDA
2.16
割高
8.39
割安
2.34

予想PSR

割安
5年平均 P/S
0.51
現在のP/S
0.16
割高
0.84
割安
0.18

Alphio AI による NUS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%NUS

$6.63

シナリオ価格

基

基本

基本 · 50%NUS

$6.29

シナリオ価格

弱

弱気

弱気 · 25%NUS

$4.75

シナリオ価格

NUS を保有するクジラ

C

Castleknight Management LP

+ を保有NUS

-5.48%

3か月リターン

イベントタイムライン

2026-08-10 (ET)

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

16:30:00

Sees Q3 Revenue of $310M to $340M

2026-05-07 (ET)

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Sees Q2 Revenue of $330M-$360M

ニュース

NUS のよくある質問 — Alphio AI が回答

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める